The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 inf...
The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo
About this item
Full title
Author / Creator
Publisher
United States: Taylor & Francis Ltd
Journal title
Language
English
Formats
Publication information
Publisher
United States: Taylor & Francis Ltd
Subjects
More information
Scope and Contents
Contents
Enterovirus 71 (EV71) causes severe central nervous system infections, leading to cardiopulmonary complications and death in young children. There is an urgent unmet medical need for new pharmaceutical agents to control EV71 infections. Using a multidisciplinary approach, we found that the approved pediatric antiparasitic drug suramin blocked EV71...
Alternative Titles
Full title
The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_570bccbd09e9427a9101bff9c6319b4b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_570bccbd09e9427a9101bff9c6319b4b
Other Identifiers
ISSN
2222-1751
E-ISSN
2222-1751
DOI
10.1038/emi.2014.60
